Discover 1,609 paid clinical trials in Raleigh, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,609
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
for
Chronic Kidney Disease and Hypertension
Location: Raleigh NC, Sanford NC, Rocky Mount NC, Kinston NC,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06742723
Phase3, Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
for
Focal Seizures
Location: Raleigh NC, Charlotte NC, Bethesda MD, Savannah GA,
Sponsor: Jazz Pharmaceuticals
Sex: All
Age: 12 - 70+
Code: NCT07233239
Phase1, Recruiting
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
for
Myasthenia Gravis
Location: Raleigh NC, Winston-Salem NC, New York NY,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18 - 70+
Code: NCT07217587
Phase3, Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
for
Focal Seizure, Epilepsy, Focal Epilepsy
Location: Raleigh NC, New York NY, Huntsville AL, Nashville TN,
Sponsor: Rapport Therapeutics Inc.
Sex: All
Age: 18 - 70+
Code: NCT07594119
Phase3, Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
for
Relapsing Multiple Sclerosis
Location: Raleigh NC, Richmond VA, Greenville SC,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 40 - 70
Code: NCT06846281
Phase3, Recruiting
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration